ストックスクリーナーアプリを入手
2.805
1.93%
-0.045
前日終値:
$2.85
開ける：
$2.85
24時間の取引高:
143.04K
Relative Volume:
0.25
時価総額：
$177.53M
収益：
-
当期純損益:
$-45.08M
株価収益率:
-3.8425
EPS:
-0.73
ネットキャッシュフロー:
$-33.68M
1週間 パフォーマンス:
+14.08%
1か月 パフォーマンス:
+16.95%
6か月 パフォーマンス:
+125.40%
1年 パフォーマンス:
+8.54%
1日の値動き範囲:
$2.78
$2.863
1週間の範囲:
$2.43
$2.97
52週間の値動き範囲:
$0.726
$3.9035
Galectin Therapeutics Inc Stock (GALT) Company Profile
名前
Galectin Therapeutics Inc
セクター
電話
678-620-3186
住所
4960 PEACHTREE INDUSTRIAL BOULEVARD, NORCROSS, GA
GALT を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GALT
Galectin Therapeutics Inc
|
2.805 | 142.41M | 0 | -45.08M | -33.68M | -0.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.55 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
551.01 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
321.59 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
569.88 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
288.26 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Galectin Therapeutics Inc Stock (GALT) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-06-17 | 再開されました | H.C. Wainwright | Buy |
| 2020-08-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-02-13 | 開始されました | B. Riley FBR | Buy |
| 2017-12-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-11-28 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-10-19 | 開始されました | ROTH Capital | Buy |
| 2017-03-30 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2016-10-03 | ダウングレード | FBR & Co. | Outperform → Mkt Perform |
| 2016-09-29 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2016-09-28 | ダウングレード | ROTH Capital | Buy → Sell |
| 2016-03-28 | 再開されました | H.C. Wainwright | Buy |
| 2015-09-21 | 開始されました | H.C. Wainwright | Buy |
| 2014-08-01 | ダウングレード | Aegis Capital | Buy → Hold |
| 2014-07-30 | 繰り返されました | MLV & Co | Buy |
| 2014-07-29 | 繰り返されました | MLV & Co | Buy |
| 2014-04-02 | 繰り返されました | MLV & Co | Buy |
| 2014-02-10 | 繰り返されました | Aegis Capital | Buy |
| 2014-01-09 | 繰り返されました | Aegis Capital | Buy |
| 2013-12-03 | 開始されました | MLV & Co | Buy |
| 2013-08-19 | 繰り返されました | Aegis Capital | Buy |
すべてを表示
Galectin Therapeutics Inc (GALT) 最新ニュース
Why Galectin Therapeutics Inc. stock attracts strong analyst attentionShort Term Risk Controlled Alerts - Newser
What makes Galectin Therapeutics Inc. stock price move sharply10x Return With Managed Risk - Newser
How Galectin Therapeutics Inc. stock performs during market volatilityFree Capital Growth Strategies - Newser
Galectin Therapeutics (NASDAQ:GALT) Share Price Crosses Above Two Hundred Day Moving AverageWhat's Next? - MarketBeat
Galectin Therapeutics announces new $10 million credit line from Richard Uihlein - MSN
Galectin Therapeutics secures $10 million credit line from board chairman By Investing.com - Investing.com South Africa
Galectin Therapeutics secures $10 million credit line from board chairman - Investing.com Australia
Galectin Therapeutics Inc. announced that it expects to receive $10 million in funding - MarketScreener
Galectin Therapeutics Secures Additional $10 million Credit Line - MarketScreener
Galectin Therapeutics Announces New $10 Million Credit Line from Richard E. Uihlein, Sufficient to Cover Expected Expenditures Through June 2026 - TradingView
Board Chairman Injects $10M Into Galectin's MASH Treatment Program: Extended Funding Through 2026 - Stock Titan
Galectin Therapeutics (NASDAQ:GALT) Share Price Passes Above 200 Day Moving AverageHere's Why - MarketBeat
Galectin Therapeutics (NASDAQ:GALT) Shares Cross Above 200 Day Moving Average – Here’s What Happened - Defense World
Galectin Therapeutics (NASDAQ:GALT) Stock Rating Upgraded by Wall Street Zen - MarketBeat
What is HC Wainwright's Estimate for GALT Q2 Earnings? - MarketBeat
Galectin's 31% Plunge: Technical Sell-off or Sector Shift? - AInvest
Galectin Therapeutics Inc. (NASDAQ:GALT) Stock Holdings Lifted by Wealth Enhancement Advisory Services LLC - Defense World
Galectin Therapeutics (NASDAQ:GALT) Now Covered by Analysts at HC Wainwright - Defense World
Galectin Therapeutics Soars 22% Amid Technical Puzzles and Retail Surge - AInvest
Galectin Therapeutics stock rating initiated at buy by H.C. Wainwright - Investing.com Nigeria
Analyst Forecast For Galectin Therapeutics Inc (NASDAQ: GALT) - Stocksregister
Galectin Therapeutics (GALT) Receives Buy Rating from H.C. Wainw - GuruFocus
HC Wainwright Initiates Coverage on Galectin Therapeutics (NASDAQ:GALT) - MarketBeat
HC Wainwright & Co. Initiates Coverage with Buy Rating on GALT | - GuruFocus
Galectin Therapeutics (GALT) Receives Buy Rating from H.C. Wainwright | GALT Stock News - GuruFocus
Galectin's 63% Surge: A Mysterious Rally in a Quiet Market - AInvest
Transcript : Galectin Therapeutics Inc.Special Call - MarketScreener
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belap - GuruFocus
Galectin Therapeutics to Host Virtual Key Opinion Leader Event on MASH Cirrhosis and Portal Hypertension Treatment - Nasdaq
Galectin Therapeutics to Host Virtual KOL Event to Discuss Belapectin for Treatment of MASH Cirrhosis and Portal Hypertension - Yahoo Finance
MASH Market Size in the 7MM was ~USD 1.8 billion in 2023, is projected to grow at a CAGR of 24%, estimates DelveInsight - The Globe and Mail
Northern Trust Corp Purchases 9,994 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics Inc (NASDAQ: GALT) Stock: Investors Need To Know This - Stocksregister
Portal Hypertension Market Growth Projections 2023-2032: - openPR.com
MASH Market Report 2034: Statistics, Revenue, Patient Pool, EMA, PDMA, FDA Approvals, Clinical Trials, Medication, MOA, ROA and Companies by DelveInsight - The Globe and Mail
Galectin Therapeutics (GALT) to Release Earnings on Thursday - MarketBeat
Galectin Therapeutics (GALT) Advances in Belapectin Analysis | G - GuruFocus
Galectin Therapeutics (GALT) Advances in Belapectin Analysis | GALT Stock News - GuruFocus
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2025 and Provides Business Update - The Manila Times
Galectin Therapeutics Reports Q1 2025 Financial Results and Business Update - TradingView
GALECTIN THERAPEUTICS INC SEC 10-Q Report - TradingView
Galectin Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Barclays PLC Purchases 26,047 Shares of Galectin Therapeutics Inc. (NASDAQ:GALT) - Defense World
Galectin Therapeutics (GALT) Projected to Post Quarterly Earnings on Wednesday - Defense World
Liver Fibrosis Market to Witness Rapid Growth at a CAGR of ~24% During the Forecast Period (2025-2034) with Emerging Treatment Options | DelveInsight - PR Newswire UK
Belapectin shows promise in MASH cirrhosis trial By Investing.com - Investing.com Canada
Galectin Therapeutics Presents NAVIGATE Study Data Of Belapectin At EASL 2025 Congress - Nasdaq
Galectin Therapeutics (GALT) Reveals Promising NAVIGATE Study Re - GuruFocus
Belapectin shows promise in MASH cirrhosis trial - Investing.com Australia
Galectin Therapeutics Updates Corporate Presentation on Belapectin - TipRanks
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress - The Manila Times
Galectin Therapeutics Inc (GALT) 財務データ
収益
当期純利益
現金流量
EPS
3.69%
2.49%
大文字化:
|
ボリューム (24 時間):